| |
 2006 NEWS ARCHIVE |
| |
| METABOLEX BEGINS PHASE 2A, PROOF-OF-CONCEPT STUDY FOR MBX-2044
DIABETES DRUG |
|
| December 20, 2006 |
|
| Metabolex, Inc., a biotechnology company dedicated to the
discovery and development of novel therapeutics for diabetes and related metabolic disorders,
announced today that it has begun a double-blind, placebo-controlled Phase 2a, proof-of-concept
study for MBX-2044, a novel oral insulin sensitizer for the treatment of type 2 diabetes ... |
| |
|
More > |
| |
| METABOLEX NAMES O’MARA, PETTY TO EXECUTIVE POSTS |
|
| November 29, 2006 |
|
| Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced today that it has promoted Patrick J. O’Mara to vice president for business development and hired Diana Petty as the company’s vice president for human resources and administration ... |
| |
|
More > |
| |
| METABOLEX RECEIVES KEY EUROPEAN PATENT FOR METAGLIDASEN |
|
| November 7, 2006 |
|
| Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced today that it has received its first European patent for metaglidasen (MBX-102), the company’s lead drug candidate ... |
| |
|
More > |
| |
| ASTELLAS BEGINS SCREENING ANOTHER TARGET FROM METABOLEX GENE DATABASE |
|
| September 12, 2006 |
|
| Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced today that Astellas Pharma Inc. has begun high-throughput screening against another target from Metabolex’s proprietary database of human genes associated with insulin resistance and obesity in order to identify potential drug candidates ... |
| |
|
More > |
| |
| METABOLEX ENTERS INTO A COMPREHENSIVE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH ORTHO-MCNEIL, INC.
FOR DRUGS FOR METABOLIC DISEASES |
|
| June 26, 2006 |
|
| Metabolex, Inc. announced today that it has entered into a comprehensive global strategic agreement with Ortho-McNeil, Inc., a Johnson & Johnson (NYSE: JNJ) company, and will collaborate on the development and commercialization of multiple programs addressing metabolic diseases, including type 2 diabetes, obesity and dyslipidemia ... |
| |
|
More > |
| |
| METABOLEX INITIATES PHASE 2/3 TRIAL OF METAGLIDASEN
IN PATIENTS WITH TYPE 2 DIABETES |
|
| June 10, 2006 |
|
| Metabolex, Inc. announced today the initiation of a Phase 2/3 trial of its lead product candidate, metaglidasen, in patients with type 2 diabetes ... |
| |
|
More > |
| |
| METABOLEX AND ASTELLAS PHARMA INC. REACH GOAL IN
DISCOVERING DRUG SCREENING TARGETS FOR DIABETES AND OBESITY |
|
| May 25, 2006 |
|
| Metabolex, Inc. today announced that Astellas Pharma Inc. has initiated a high throughput screen on a previously selected target and has chosen an additional validated target for drug screening and development through its research and development collaboration with Metabolex ... |
| |
|
More > |
| |
| METABOLEX CEO TO PARTICIPATE IN BREAK-OUT SESSION
AT BIO 2006 ANNUAL INTERNATIONAL CONVENTION |
|
| April 10, 2006 |
|
| Metabolex, Inc. today announced that Harold E. Van Wart, Ph.D., president and CEO of Metabolex, will speak on a panel at the Biotechnology Industry Organization (BIO) 2006 Annual International Convention ... |
| |
|
More > |
| |
| PRECLINICAL
STUDY RESULTS SHOW METAGLIDASEN IS AS EFFECTIVE AS ROSIGLITAZONE
AND PIOGLITAZONE IN CONTROLLING BLOOD GLUCOSE AND LOWERING
LIPIDS, WITH AN IMPROVED SIDE EFFECT PROFILE |
|
| January 24, 2006 |
|
| Metabolex, Inc. today
announced findings showing the molecular and cellular
differences between metaglidasen, a novel oral insulin
sensitizer in clinical development for the treatment
of type 2 diabetes ... |
|
| |
|
More > |
